Thyroid Gland Papillary Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Thyroid Gland Carcinoma (357)

Thyroid Gland Anaplastic Carcinoma (69)

Thyroid Gland Medullary Carcinoma (61)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Hurthle Cell Carcinoma (12)

Thyroid Gland Carcinoma (357)

Thyroid Gland Anaplastic Carcinoma (69)

Thyroid Gland Medullary Carcinoma (61)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Hurthle Cell Carcinoma (12)

›

NTRK2 fusion	Thyroid Gland Papillary Carcinoma	NTRK2 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
NTRK3 fusion	Thyroid Gland Papillary Carcinoma	NTRK3 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
NTRK1 fusion	Thyroid Gland Papillary Carcinoma	NTRK1 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week (New C4) larotrectinib Sensitive : A2 ATA 2023 - 1wk	larotrectinib Sensitive: A2 - Guideline ATA 2023 - 1 week larotrectinib Sensitive : A2 ATA 2023 - 1 week - (New C4)
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label ATA 2023 - 1 week (New C4) trametinib + dabrafenib Sensitive : C1 ATA 2023 - 1wk	trametinib + dabrafenib Sensitive: C1 - Off-label ATA 2023 - 1 week trametinib + dabrafenib Sensitive : C1 ATA 2023 - 1 week - (New C4)
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2	denosumab Sensitive: A2 - Guideline denosumab Sensitive : A2
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Papillary Carcinoma	NTRK3 fusion	Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Papillary Carcinoma	NTRK2 fusion	Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Papillary Carcinoma	NTRK1 fusion	Thyroid Gland Papillary Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
TMB-H	Thyroid Gland Papillary Carcinoma	TMB-H	Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
MSI-H/dMMR	Thyroid Gland Papillary Carcinoma	MSI-H/dMMR	Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1	vemurafenib + cobimetinib Sensitive: C1 - Off-label vemurafenib + cobimetinib Sensitive : C1
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C1 - Off-label dabrafenib Sensitive : C1	dabrafenib Sensitive: C1 - Off-label dabrafenib Sensitive : C1
BRAF mutation	Thyroid Gland Papillary Carcinoma	BRAF mutation	Thyroid Gland Papillary Carcinoma	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF mutation	Thyroid Gland Papillary Carcinoma	BRAF mutation	Thyroid Gland Papillary Carcinoma	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3	BGB-283 Sensitive: C3 – Early Trials BGB-283 Sensitive : C3
BRAF mutation	Thyroid Gland Papillary Carcinoma	BRAF mutation	Thyroid Gland Papillary Carcinoma	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3	dabrafenib Sensitive: C3 – Early Trials dabrafenib Sensitive : C3
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
BRAF mutation	Thyroid Gland Papillary Carcinoma	BRAF mutation	Thyroid Gland Papillary Carcinoma	trametinib + dabrafenib Sensitive: C3 – Early Trials trametinib + dabrafenib Sensitive : C3	trametinib + dabrafenib Sensitive: C3 – Early Trials trametinib + dabrafenib Sensitive : C3
BRAF V600	Thyroid Gland Papillary Carcinoma	BRAF V600	Thyroid Gland Papillary Carcinoma	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3	FORE-8394 Sensitive: C3 – Early Trials FORE-8394 Sensitive : C3
BRAF V600E	Thyroid Gland Papillary Carcinoma	BRAF V600E	Thyroid Gland Papillary Carcinoma	siltuximab Sensitive: C4 – Case Studies siltuximab Sensitive : C4	siltuximab Sensitive: C4 – Case Studies siltuximab Sensitive : C4
PDGFRB overexpression	Thyroid Gland Papillary Carcinoma	PDGFRB overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
EGFR overexpression	Thyroid Gland Papillary Carcinoma	EGFR overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma	NCOA4-RET fusion	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4	lenvatinib Sensitive: C4 – Case Studies lenvatinib Sensitive : C4
TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	AB-106 Sensitive: C4 – Case Studies AB-106 Sensitive : C4	AB-106 Sensitive: C4 – Case Studies AB-106 Sensitive : C4
GLI3 overexpression	Thyroid Gland Papillary Carcinoma	GLI3 overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
GLI2 overexpression	Thyroid Gland Papillary Carcinoma	GLI2 overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
GLI1 overexpression	Thyroid Gland Papillary Carcinoma	GLI1 overexpression	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4
TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	TPM3-NTRK1 fusion	Thyroid Gland Papillary Carcinoma	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4	larotrectinib Sensitive: C4 – Case Studies larotrectinib Sensitive : C4

Thyroid Gland Papillary Carcinoma

Associations(57)

Associations
(57)